Ventas, Inc.: Wells Fargo raises target price to $102 from $96
VTR•Wells Fargo raised its target price for Ventas to $102 from $96.
Related News

Anteris announces presentation of one-year DurAVR outcomes in 100 patients at PCR Valves conference
AVR•

XTI Aerospace COO Michael A. Tapp resigns, effective immediately
XTIA•

Pavella Therapeutics initiates coverage with outperform rating; target price $228
PVLA•

Immix Biopharma target price raised to $27 from $25
IMMX•

Wells Fargo cuts Cogent Communications target price to $4 from $14
CCOI•